AGN — Argenica Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- AU$56.52m
- AU$48.09m
- AU$0.06m
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 0 | 0 | 0.003 | 0.061 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Unusual Expense / Income | ||||
Other Operating Expenses | ||||
Total Operating Expenses | 0.384 | 1.33 | 4.35 | 6.62 |
Operating Profit | -0.383 | -1.33 | -4.35 | -6.56 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -0.383 | -1.03 | -4.09 | -4.82 |
Provision for Income Taxes | ||||
Net Income After Taxes | -0.383 | -1.03 | -4.09 | -4.82 |
Net Income Before Extraordinary Items | ||||
Net Income | -0.383 | -1.03 | -4.09 | -4.82 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -0.383 | -1.03 | -4.09 | -4.82 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.005 | -0.012 | -0.054 | -0.054 |
Dividends per Share |